260 likes | 398 Vues
This document outlines the ambitious project aimed at barcoding ancient DNA specimens, defined as over 100 years old. We explore the project's goals—developing efficient protocols for various Lepidoptera families—while addressing significant obstacles like small tissue sizes and contamination. Current progress indicates a 65% success rate in sample processing. With solutions such as universal primers and sterile practices, we aim to enhance taxonomic clarity and resolve cryptic species complexes. Preliminary findings provide insight into the future of ancient DNA research.
E N D
Barcoding Type Specimens Goals, Obstacles, and Current Progress
Outline • Ancient DNA • Project overview • Purpose • Primary goals • Obstacles and solutions • Current progress • Preliminary findings • Future prospects
A primer on ancient DNA • >100 years old is considered "ancient” Quality (%) Age(yrs)
Outline • Ancient DNA • Project overview • Purpose • Primary goals • Obstacles and solutions • Current progress • Preliminary findings • Future prospects
Why barcode type specimens? • Barcode database construction • Helps put names to faces • Establish links to modern specimens • Taxonomic clarification • Help resolve cryptic species complexes • Help resolve unnecessary splits
Primary goals • Develop type specimen protocol • Effective, cheap, high-throughput • Apply protocol to: • ~3000 geometrids • ~300 xyloryctids • Other Lepidoptera families • Other orders
Oldest legitimate DNA? 130,000 years old 45,000 years old 700,000 years old
Obstacles • Small tissue size = less DNA • Some legs <10 ug • 100,000 fold less template than standard ancient bone samples • Variable killing and storage conditions • Variable handling over the decades 400 mg 0.04 mg
Solutions: Tissue size • Abdominal lysates • Alternative to legs • Made prior to dissections • More DNA than a single leg • Concentrate DNA extract • Increase PCR cycles
Additional obstacles • Project specific • Hundreds of species • Universal primers • Contaminants • Universal primers may also amplify contaminants • Cannot wash or take "core" sample from tissue • High-throughput • Must be cost effective • Cannot extensively focus on any one sample
Solutions: Many species • Universal primers • Degenerate primers • Primer cocktail • Target conserved yet hypervariable region • 164 bp region of COI • Second attempt for specimens that failed first pass • 94 bp region of COI 164 bp 94 bp 658 bp BARCODE
Solutions: Contamination • Dedicated room, equipment, reagents, and workstations • Sterile practices • Full body suit, hood, mask, gloves • Frequent glove changes • Avoid working over samples • Avoid generating aerosols
Outline • Ancient DNA • Project overview • Purpose • Primary goals • Obstacles and solutions • Current progress • Preliminary findings • Future prospects
Type Specimen Protocol EXTRACTION LYSIS DNA (94 bp) (non-destructive) (single column) PCR SEQUENCING EDITING (164 bp) (658 bp)
Current Progress • Processed: • Geometridae: 948/3000 (32% complete) • Xyloryctidae: 224/300 (75% complete) • Other: 383/383 (100% complete) • Total:1555/3683 (42% complete) • Success: • Geometridae: 629/948 = 66% • Xyloryctidae: 103/224 = 46% • Other: 278/383 = 73% • Total: 1010/1555 = 65%
Outline • Ancient DNA • Project overview • Purpose • Primary goals • Obstacles and solutions • Current progress • Preliminary findings • Future prospects
Factors affecting success • Taxonomy • Tissue size • Primer binding efficiency • Age • Killing method • Handling • Storage
Outline • Ancient DNA • Project overview • Purpose • Primary goals • Obstacles and solutions • Current progress • Preliminary findings • Future prospects
Destructive processing • Pre-lysis tissue grinding • Applicable to dry legs • Hypothesis: Grinding tissue prior to lysis will increase accessibility of DNA
Real-time PCR • Monitor amplification in real-time • Sequence ONLY true positives Human Contaminants REAL Primer Dimers
Further Experiments • Samples: Ancient lep specimens we can destroy • Allows us to measure one variable while controlling all others • Test: • Pre-lysis tissue treatments • Tissue types • Size (i.e. mass) • Primer binding efficiency
Acknowledgments Funding provided by: